Approvals (Drugs@FDA)

UPTRAVI

ACTELION · SELEXIPAG

NDA214275Drug (NDA)Prescription
Open FDA's page for this record
Application number
NDA214275
Sponsor name
ACTELION
Submissions
  1. Submission type
    SUPPL
    Submission number
    2
    Submission status
    AP
    Submission status date
    20260523
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      86052
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207947Orig1s014; s015; 214275Orig1s002ltr.pdf
      Date
      20260527
      Type
      Letter
    2. ID
      86130
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207947Orig1s014,s015;214275Orig1s002lbl.pdf
      Date
      20260911
      Type
      Label
  2. Submission type
    ORIG
    Submission number
    1
    Submission status
    AP
    Submission status date
    20210729
    Review priority
    STANDARD
    Submission class code
    TYPE 3
    Submission class code description
    Type 3 - New Dosage Form
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      68248
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214275Orig1s000ltr.pdf
      Date
      20210802
      Type
      Letter
    2. ID
      68260
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214275s000lbl.pdf
      Date
      20210802
      Type
      Label
    3. ID
      69131
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214275Orig1s000TOC.html
      Date
      20211027
      Type
      Review
Products
  1. Product number
    001
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    Yes
    Dosage form
    POWDER
    Route
    INTRAVENOUS
    Marketing status
    Prescription
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      1.8MG/VIAL
Harmonized identifiers (openFDA)
Application number
NDA214275
Brand name
UPTRAVI
Generic name
SELEXIPAG
Manufacturer name
Actelion Pharmaceuticals US, Inc.
Product NDC
66215-718, 66215-602, 66215-604, 66215-606, 66215-608, 66215-610, 66215-612, 66215-614, 66215-616, 66215-628, 66215-910, 66215-915
Product type
HUMAN PRESCRIPTION DRUG
Route
INTRAVENOUS
Substance name
SELEXIPAG
RxCUI
1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288
SPL ID
7c54a125-9778-41f5-b92c-181711e22e06
SPL set ID
a7a23b87-f892-4e2c-8e2e-ebf841220f90
Package NDC
66215-602-06, 66215-602-14, 66215-604-06, 66215-606-06, 66215-608-06, 66215-610-06, 66215-612-06, 66215-614-06, 66215-616-06, 66215-628-20, 66215-718-01, 66215-910-14, 66215-915-14
Nui
N0000192339, N0000020068
Pharm class epc
Prostacyclin Receptor Agonist [EPC]
Pharm class moa
Prostacyclin Receptor Agonists [MoA]
UNII
5EXC0E384L
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.